1. Explain the general nature of inter-patient and intra-tumoral heterogeneity in triple-negative breast cancer.
2. Identify recently FDA-approved therapy and remaining unmet medical needs in TNBC.
Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=e9719cf345e9a5880da9a903fdf04524f
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours